Related references
Note: Only part of the references are listed.Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)
Borghaei
JOURNAL OF CLINICAL ONCOLOGY (2021)
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
Makoto Nishio et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials
Julien Mazieres et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2021)
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC
Roy S. Herbst et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
Michael Boyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
B.C. Cho et al.
Journal of Thoracic Oncology (2021)
97O First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407
A.G. Robinson et al.
Journal of Thoracic Oncology (2021)
96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial
C. Zhou et al.
Journal of Thoracic Oncology (2021)
P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC
N. Patil et al.
Journal of Thoracic Oncology (2021)
FP13.03 IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1–Selected NSCLC
R. Herbst et al.
Journal of Thoracic Oncology (2021)
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
J. Gray et al.
Journal of Thoracic Oncology (2021)
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial
Jie Wang et al.
JAMA ONCOLOGY (2021)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
Evan J. Lipson et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Shun Lu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >= 50%
J. F. Gainor et al.
ANNALS OF ONCOLOGY (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Marina C Garassino et al.
LANCET ONCOLOGY (2020)
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.
Marina Chiara Garassino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert Jotte et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
IMpower150: Updated efficacy analysis in patients with EGFR mutations
M. Reck et al.
ANNALS OF ONCOLOGY (2020)
Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) plus chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC
M. Nishio et al.
ANNALS OF ONCOLOGY (2020)
ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC)
C. Zhou et al.
ANNALS OF ONCOLOGY (2020)
IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
H. West et al.
ANNALS OF ONCOLOGY (2020)
Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
M-J. Ahn et al.
ANNALS OF ONCOLOGY (2020)
Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC
J. Niu et al.
ANNALS OF ONCOLOGY (2020)
EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%
A. Sezer et al.
ANNALS OF ONCOLOGY (2020)
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yunpeng Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A phase I study of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb: Biomarker analyses from the microsatellite stable metastatic colorectal cancer (MSS mCRC) cohort
Johanna Bendell et al.
CANCER RESEARCH (2020)
GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an antiPDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)
C. Zhou et al.
ANNALS OF ONCOLOGY (2020)
How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
S. Peters et al.
ANNALS OF ONCOLOGY (2019)
Negative Co-stimulation Constrains T Cell Differentiation by Imposing Boundaries on Possible Cell States
Spencer C. Wei et al.
IMMUNITY (2019)
Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy
Bernardo L. Rapoport et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
Yu Kato et al.
PLOS ONE (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Randomized, double-blind, phase 3 trial of first-line pembrolizumab plus platinum doublet chemotherapy (chemo) lenvatinib in patients (pts) with metastatic nonsquamous non small-cell lung cancer (NSCLC): LEAP-006.
Rina Hui et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Howard West et al.
LANCET ONCOLOGY (2019)
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice
Martin Faehling et al.
ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
E. J. Aguilar et al.
ANNALS OF ONCOLOGY (2019)
LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC
S Gadgeel et al.
ANNALS OF ONCOLOGY (2019)
Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
M. Garassino et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
Koichi Suyama et al.
CANCER CONTROL (2018)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Share Paper
